

PATENT
CASE SY01106KQ1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----X
In re Application of: :
Wild et al. :
 : Examiner: Brumback, B.
For Patent For: :
RECOMBINANT LARYNGOTRACHEITIS : Group Art Unit: 1642
VIRUS AND USES THEREOF :
 :
Serial No.: To be assigned : Date: November 6, 2001
Filed: November 6, 2001 :
-----X

Schering-Plough Corporation
Kenilworth, New Jersey 07033-0530

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows.

IN THE SPECIFICATION

On page 1 of the specification, please delete lines 5-7, the first paragraph of the specification, and substitute the following:

--This application is a continuation of application U.S. Serial No. 08/468,190 filed June 6, 1995 which is a continuation of U.S. Serial No. 08/410,121 filed March 23, 1995 which is a continuation-in-part of U.S. Serial No. 08/126,597 filed September 24, 1993.--

On page 179 of the specification, please delete lines 7-20, the three paragraphs of the abstract, and replace these paragraphs with the following:

EXPRESS MAIL LABEL NO.: EL 403236015US

--Recombinant, attenuated infectious laryngotracheitis viruses containing a deletion or deletions in a glycoprotein gene are provided. Also provided are glycoprotein genes, gD, gI, gG and gE as well as other viral genes.--

IN THE CLAIMS

Please cancel claims 39-55, 60-69, 71-72 and 79-86 without prejudice. Applicant wishes to pursue previously cancelled claims 56-59, 70, and 73-78. Support for these claims can be specifically found on page 29, lines 8-9, page 50, lines 14-24, the sequence listing, and elsewhere throughout the specification.

The pending claims are thus as follows:

56. An isolated nucleic acid molecule encoding an infectious laryngotracheitis virus glycoprotein I.

57. The isolated nucleic acid molecule of claim 56, wherein the isolated nucleic acid molecule is genomic DNA.

58. The isolated nucleic acid molecule of claim 56, wherein the isolated nucleic acid molecule is cDNA.

59. An isolated RNA molecule which is derived from the isolated nucleic acid molecule of claim 56.

70. A method of diagnosing which comprises: (a) obtaining a nucleic acid molecule from a suitable bodily fluid of a subject; (b) contacting the nucleic acid molecule with the labelled nucleic

acid molecule of claim 56 under hybridizing conditions; and (c) determining the presence of the nucleic acid molecule hybridized, the presence of which is indicative of infectious laryngotracheitis virus glycoprotein I in the subject thereby diagnosing infectious laryngotracheitis virus.

73. A recombinant DNA molecule comprising DNA encoding infectious laryngotracheitis virus glycoprotein I.

74. The recombinant DNA molecule of claim 73, wherein the DNA encoding the infectious laryngotracheitis virus glycoprotein I comprises genomic DNA.

75. The recombinant DNA molecule of claim 73, wherein the DNA encoding the infectious laryngotracheitis virus glycoprotein I is operatively linked to a regulatory element.

76. The recombinant DNA molecule of claim 73, wherein the recombinant DNA molecule further comprises DNA encoding infectious laryngotracheitis virus glycoprotein D.

77. A host cell comprising the recombinant DNA molecule of claim 73.

78. A host cell comprising the recombinant DNA molecule of claim 76.

Applicant notes that a computer (disk) copy of the sequence listing has already been filed in the parent case. Applicant is submitting a Request for Transfer of Computer Readable Form of Sequence Listing along with this Preliminary Amendment.

SCHERING-PLOUGH CORPORATION

Patent Department, K-6-1, 1990


2000 Galloping Hill Road

Kenilworth, NJ 07033-0530

908-298-2135

Date: November 6, 2001

Respectfully submitted



PAMELA G. SALKELD

Reg. No. 38607

Attorney for Applicants

(908) 298-2135